PGF2α-F-prostanoid receptor signalling via ADAMTS1 modulates epithelial cell invasion and endothelial cell function in endometrial cancer

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Keightley, Margaret C ^a   Sales, Kurt J ^a   Jabbour, Henry N ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMTS1 PROTEIN; CD31 ANTIGEN; ESTRADIOL; F PROSTANOID RECEPTOR; IMMUNOGLOBULIN G; MESSENGER RNA; PROGESTERONE; PROSTAGLANDIN F2 ALPHA; PROSTANOID RECEPTOR; UNCLASSIFIED DRUG; ADAM PROTEIN; ADAMTS1 PROTEIN, HUMAN; CALMODULIN; PROSTAGLANDIN F2ALPHA RECEPTOR; PROSTAGLANDIN RECEPTOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NFAT;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL DIFFERENTIATION; CELL FUNCTION; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; ENDOTHELIUM CELL; EPITHELIUM CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTRACELLULAR SIGNALING; MENSTRUAL CYCLE; PARACRINE SIGNALING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS REGULATION; QUANTITATIVE ANALYSIS; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR BIOPSY; ADENOCARCINOMA; APOPTOSIS; CELL ADHESION; CELL CULTURE; CELL MOTION; CULTURE MEDIUM; CYTOLOGY; DRUG ANTAGONISM; ENDOMETRIUM; ENDOMETRIUM TUMOR; ENZYME IMMUNOASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; UMBILICAL VEIN; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

ADAM PROTEINS; ADENOCARCINOMA; ADULT; AGED; APOPTOSIS; BLOTTING, WESTERN; CALMODULIN; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; DINOPROST; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; ENDOTHELIUM, VASCULAR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NFATC TRANSCRIPTION FACTORS; RECEPTORS, PROSTAGLANDIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; UMBILICAL VEINS; YOUNG ADULT;

EID: 77956477584     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-488     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009, 59(4):225-249. 10.3322/caac.20006, 19474385.
2. Doll A, Abal M, Rigau M, Monge M, Gonzalez M, Demajo S, Colas E, Llaurado M, Alazzouzi H, Planaguma J, Lohmann MA, Garcia J, Castellvi S, Ramon y Cajal J, Gil-Moreno A, Xercavins J, Alameda F, Reventos J. Novel molecular profiles of endometrial cancer-new light through old windows. J Steroid Biochem Mol Biol 2008, 108(3-5):221-229. 10.1016/j.jsbmb.2007.09.020, 18061438.
3. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004, 4(8):579-591. 10.1038/nrc1408, 15286738.
4. Shang Y. Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nat Rev Cancer 2006, 6(5):360-368. 10.1038/nrc1879, 16633364.
5. Tong BJ, Tan J, Tajeda L, Das SK, Chapman JA, DuBois RN, Dey SK. Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma. Neoplasia 2000, 2(6):483-490. 10.1038/sj.neo.7900119, 1508090, 11228540.
6. Jabbour HN, Milne SA, Williams AR, Anderson RA, Boddy SC. Expression of COX-2 and PGE synthase and synthesis of PGE2 in endometrial adenocarcinoma: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. Br J Cancer 2001, 85(7):1023-1031.
7. Sales KJ, Milne SA, Williams AR, Anderson RA, Jabbour HN. Expression, localization, and signaling of prostaglandin F2 alpha receptor in human endometrial adenocarcinoma: regulation of proliferation by activation of the epidermal growth factor receptor and mitogen-activated protein kinase signaling pathways. J Clin Endocrinol Metab 2004, 89(2):986-993. 10.1210/jc.2003-031434, 14764825.
8. Jabbour HN, Sales KJ, Boddy SC, Anderson RA, Williams AR. A positive feedback loop that regulates cyclooxygenase-2 expression and prostaglandin F2alpha synthesis via the F-series-prostanoid receptor and extracellular signal-regulated kinase 1/2 signaling pathway. Endocrinology 2005, 146(11):4657-4664. 10.1210/en.2005-0804, 16081631.
9. Sales KJ, Boddy SC, Williams AR, Anderson RA, Jabbour HN. F-prostanoid receptor regulation of fibroblast growth factor 2 signaling in endometrial adenocarcinoma cells. Endocrinology 2007, 148(8):3635-3644. 10.1210/en.2006-1517, 17478553.
10. Sales KJ, List T, Boddy SC, Williams AR, Anderson RA, Naor Z, Jabbour HN. A novel angiogenic role for prostaglandin F2alpha-FP receptor interaction in human endometrial adenocarcinomas. Cancer Res 2005, 65(17):7707-7716. 2694301, 16140938.
11. Keightley MC, Brown P, Jabbour HN, Sales KJ. F-Prostaglandin receptor regulates endothelial cell function via fibroblast growth factor-2. BMC Cell Biol 2010, 11:8. 10.1186/1471-2121-11-8, 2824741, 20092633.
12. Sales KJ, Boddy SC, Jabbour HN. F-prostanoid receptor alters adhesion, morphology and migration of endometrial adenocarcinoma cells. Oncogene 2008, 27(17):2466-2477. 10.1038/sj.onc.1210883, 2694991, 17968320.
13. Fujino H, Regan JW. Prostanoid receptors and phosphatidylinositol 3-kinase: a pathway to cancer?. Trends in pharmacological sciences 2003, 24(7):335-340. 10.1016/S0165-6147(03)00162-7, 12871665.
14. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997, 94(7):3336-3340. 10.1073/pnas.94.7.3336, 20370, 9096394.
15. Abulafia O, Triest WE, Sherer DM, Hansen CC, Ghezzi F. Angiogenesis in endometrial hyperplasia and stage I endometrial carcinoma. Obstet Gynecol 1995, 86(1):479-485.
16. Masui T, Hosotani R, Tsuji S, Miyamoto Y, Yasuda S, Ida J, Nakajima S, Kawaguchi M, Kobayashi H, Koizumi M, Toyoda E, Tulachan S, Arii S, Doi R, Imamura M. Expression of METH-1 and METH-2 in Pancreatic Cancer. Clinical Cancer Research 2001, 7(11):3437-3443.
17. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, Guise TA, Massagué J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3(6):537-549. 10.1016/S1535-6108(03)00132-6, 12842083.
18. Kuno K, Kanada N, Nakashima E, Fujiki F, Ichimura F, Matsushima K. Molecular cloning of a gene encoding a new type of metalloproteinase-disintegrin family protein with thrombospondin motifs as an inflammation associated gene. J Biol Chem 1997, 272(1):556-562. 10.1074/jbc.272.1.556, 8995297.
19. Kuno K, Matsushima K. ADAMTS-1 protein anchors at the extracellular matrix through the thrombospondin type I motifs and its spacing region. J Biol Chem 1998, 273(22):13912-13917. 10.1074/jbc.273.22.13912, 9593739.
20. Sales KJ, Maldonado-Perez D, Grant V, Catalano RD, Wilson MR, Brown P, Williams AR, Anderson RA, Thompson EA, Jabbour HN. Prostaglandin F2alpha-F-prostanoid receptor regulates CXCL8 expression in endometrial adenocarcinoma cells via the calcium-calcineurin-NFAT pathway. Biochim Biophys Acta 2009, 1793(12):1917-1928. 10.1016/j.bbamcr.2009.09.018, 2806519, 19819266.
21. Sales KJ, Katz AA, Millar RP, Jabbour HN. Seminal plasma activates cyclooxygenase-2 and prostaglandin E2 receptor expression and signalling in cervical adenocarcinoma cells. Mol Hum Reprod 2002, 8(12):1065-1070. 10.1093/molehr/8.12.1065, 2694307, 12468638.
22. Battersby S, Sales KJ, Williams AR, Anderson RA, Gardner S, Jabbour HN. Seminal plasma and prostaglandin E2 up-regulate fibroblast growth factor 2 expression in endometrial adenocarcinoma cells via E-series prostanoid-2 receptor-mediated transactivation of the epidermal growth factor receptor and extracellular signal-regulated kinase pathway. Hum Reprod 2007, 22(1):36-44. 10.1093/humrep/del328, 2694993, 16905765.
23. Kleinman HK, Jacob K. Invasion assays. Curr Protoc Cell Biol 2001, Chapter 12(Unit 12):12.
24. Iruela-Arispe ML, Carpizo D, Luque A. ADAMTS1: a matrix metalloprotease with angioinhibitory properties. Ann N Y Acad Sci 2003, 995:183-190. 10.1111/j.1749-6632.2003.tb03221.x, 12814950.
25. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100(1):57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
26. Gatenby RA, Gillies RJ. A microenvironmental model of carcinogenesis. Nat Rev Cancer 2008, 8(1):56-61. 10.1038/nrc2255, 18059462.
27. Yiu GK, Toker A. NFAT induces breast cancer cell invasion by promoting the induction of cyclooxygenase-2. J Biol Chem 2006, 281(18):12210-12217. 10.1074/jbc.M600184200, 16505480.
28. Lu X, Wang Q, Hu G, Van Poznak C, Fleisher M, Reiss M, Massaguà J, Kang Y. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes & Development 2009, 23(16):1882-1894.
29. Milne SA, Jabbour HN. Prostaglandin (PG) F2alpha receptor expression and signaling in human endometrium: role of PGF2alpha in epithelial cell proliferation. J Clin Endocrinol Metab 2003, 88(4):1825-1832. 10.1210/jc.2002-021368, 12679480.
30. Ng YH, Zhu H, Pallen CJ, Leung PC, MacCalman CD. Differential effects of interleukin-1beta and transforming growth factor-beta1 on the expression of the inflammation-associated protein, ADAMTS-1, in human decidual stromal cells in vitro. Hum Reprod 2006, 21(8):1990-1999. 10.1093/humrep/del108, 16675485.
31. Fujino H, Regan JW. Prostaglandin F2alpha stimulation of cyclooxygenase-2 promoter activity by the FPB prostanoid receptor. Eur J Pharmacol 2003, 465(1-2):39-41. 10.1016/S0014-2999(03)01485-7, 12650831.
32. Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 1997, 15:707-747. 10.1146/annurev.immunol.15.1.707, 9143705.
33. Lu H, Huan C. Transcription factor NFAT, its role in cancer development, and as a potential target for chemoprevention. Curr Cancer Drug Targets 2007, 7(4):343-353. 10.2174/156800907780809750, 17979629.
34. Hatipoglu OF, Hirohata S, Cilek MZ, Ogawa H, Miyoshi T, Obika M, Demircan K, Shinohata R, Kusachi S, Ninomiya Y. ADAMTS1 is a unique hypoxic early response gene expressed by endothelial cells. The Journal of biological chemistry 2009, 284(24):16325-16333. 10.1074/jbc.M109.001313, 2713541, 19349275.
35. Krampert M, Kuenzle S, Thai SN, Lee N, Iruela-Arispe ML, Werner S. ADAMTS1 proteinase is up-regulated in wounded skin and regulates migration of fibroblasts and endothelial cells. The Journal of biological chemistry 2005, 280(25):23844-23852. 10.1074/jbc.M412212200, 15843381.
36. Kuno K, Okada Y, Kawashima H, Nakamura H, Miyasaka M, Ohno H, Matsushima K. ADAMTS-1 cleaves a cartilage proteoglycan, aggrecan. FEBS Lett 2000, 478(3):241-245. 10.1016/S0014-5793(00)01854-8, 10930576.
37. Rodriguez-Manzaneque JC, Westling J, Thai SN, Luque A, Knauper V, Murphy G, Sandy JD, Iruela-Arispe ML. ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors. Biochem Biophys Res Commun 2002, 293(1):501-508. 10.1016/S0006-291X(02)00254-1, 12054629.
38. Rodriguez-Manzaneque JC, Carpizo D, Plaza-Calonge Mdel C, Torres-Collado AX, Thai SN, Simons M, Horowitz A, Iruela-Arispe ML. Cleavage of syndecan-4 by ADAMTS1 provokes defects in adhesion. Int J Biochem Cell Biol 2009, 41(4):800-810. 10.1016/j.biocel.2008.08.014, 18775505.
39. Esselens C, Malapeira J, Colome N, Casal C, Rodriguez-Manzaneque JC, Canals F, Arribas J. The cleavage of semaphorin 3C induced by ADAMTS1 promotes cell migration. J Biol Chem 2010, 285(4):2463-2473. 10.1074/jbc.M109.055129, 19915008.
40. Liu YJ, Xu Y, Yu Q. Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively. Oncogene 2006, 25(17):2452-2467. 10.1038/sj.onc.1209287, 2759703, 16314835.
41. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009, 41(5):619-624. 10.1038/ng.370, 2835150, 19396168.
42. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. 2003, 3(6):401-410.
43. Margosio B, Rusnati M, Bonezzi K, Cordes BL, Annis DS, Urbinati C, Giavazzi R, Presta M, Ribatti D, Mosher DF, Taraboletti G. Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain. Int J Biochem Cell Biol 2008, 40(4):700-709. 10.1016/j.biocel.2007.10.002, 2346532, 17996481.
44. Lee NV, Sato M, Annis DS, Loo JA, Wu L, Mosher DF, Iruela-Arispe ML. ADAMTS1 mediates the release of antiangiogenic polypeptides from TSP1 and 2. Embo J 2006, 25(22):5270-5283. 10.1038/sj.emboj.7601400, 1636613, 17082774.
45. Abdollahi A, Hahnfeldt P, Maercker C, Grone HJ, Debus J, Ansorge W, Folkman J, Hlatky L, Huber PE. Endostatin's antiangiogenic signaling network. Mol Cell 2004, 13(5):649-663. 10.1016/S1097-2765(04)00102-9, 15023336.
46. Schumacher JJ, Dings RP, Cosin J, Subramanian IV, Auersperg N, Ramakrishnan S. Modulation of angiogenic phenotype alters tumorigenicity in rat ovarian epithelial cells. Cancer Res 2007, 67(8):3683-3690. 10.1158/0008-5472.CAN-06-3608, 17440080.
47. Kyriakides TR, Zhu YH, Yang Z, Huynh G, Bornstein P. Altered extracellular matrix remodeling and angiogenesis in sponge granulomas of thrombospondin 2-null mice. Am J Pathol 2001, 159(4):1255-1262. 1850515, 11583953.
48. Luque A, Carpizo DR, Iruela-Arispe ML. ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165. J Biol Chem 2003, 278(26):23656-23665. 10.1074/jbc.M212964200, 12716911.